Clinical trial · Interventional
Vascular Anomaly Pathology and Genomics Biopsy Study
Validation of Core Biopsy of Vascular Anomalies for Clinical Pathology and Genomics
NCT04836884CI-TRIAL-00057959completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this research is to gather information on the safety and effectiveness of core biopsy of vascular anomalies for clinical pathology and clinical genomics studies.
Conditions
Conditions (7)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Arteriovenous Malformations | — | UNRESOLVED | — |
| Hemangioma | Hemangioma | ONTOLOGY_EXACT | 0.98 |
| Klippel Trenaunay Syndrome | — | UNRESOLVED | — |
| Lymphatic Malformation | — | UNRESOLVED | — |
| Vascular Anomaly | — | UNRESOLVED | — |
| Vascular Malformations | — | UNRESOLVED | — |
| Venous Malformation | Venous Hemangioma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Percutaneous Vascular Anomaly/Malformation Biopsy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Vascular anomaly/malformation biopsy
- description
- Subjects with a vascular anomaly will have a research percutaneous vascular anomaly/malformation biopsy completed at the time of the clinically indicated percutaneous sclerotherapy, embolization and/or ablation.
- interventionNames
- Procedure: Percutaneous Vascular Anomaly/Malformation Biopsy
Primary outcomes (2)
- measure
- Adequacy of core biopsy of vascular anomalies for clinical genomics studies
- timeFrame
- 18 months
- description
- DNA and RNA will be extracted from the biopsy specimens, undergo qualitative/quantitative quality control assessment and be analyzed by whole genome sequencing (DNA) and RNA sequence analysis (RNA-seq) to determine the adequacy of vascular anomaly biopsy for vascular anomaly genomics characterization.
- measure
- Adequacy of core biopsy of vascular anomalies for clinical pathology evaluation
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with a clinical and imaging diagnosis of a vascular anomaly. * No prior treatment for the vascular anomaly. * Subjects undergoing clinically indicated sclerotherapy, embolization and/or ablation. * Male or female with age greater than or equal to 18 years. * Capacity and willingness to provide a written informed consent.. Exclusion Criteria: * Subjects with prior treatment for their vascular anomaly. * Uncorrectable coagulopathy. * Pregnant and/or breast-feeding subjects. A negative pregnancy test within 48 hours of the procedure.
References
Publications (0)
Data not yet available
No reference posted for this study.